3 results
Primary objectives Phase I: To determine the recommended phase 2 dose (RP2D) of the lapatinib-trametinib combination in patients with KRASm NSCLC Phase II: To determine the progression free survival of the lapatinib-trametinib combination compared…
Primary: The co-primary objectives of this study are* to compare independently adjudicated progression-free survival (PFS) following treatment with neratinib pluscapecitabine versus lapatinib plus capecitabine in patients with HER2-positive (HER2+)…
Main objective- To characterize the effect of GLPG2737 on growth in total kidneyvolume (TKV) compared to placebo.- To evaluate the safety and tolerability of oral doses of GLPG2737compared to placebo.Secondary objectives: - To characterize the…